[go: up one dir, main page]

DK1677735T3 - Fremgangsmåder og sammensætninger til modulering af adipocytfunktion - Google Patents

Fremgangsmåder og sammensætninger til modulering af adipocytfunktion

Info

Publication number
DK1677735T3
DK1677735T3 DK04795629T DK04795629T DK1677735T3 DK 1677735 T3 DK1677735 T3 DK 1677735T3 DK 04795629 T DK04795629 T DK 04795629T DK 04795629 T DK04795629 T DK 04795629T DK 1677735 T3 DK1677735 T3 DK 1677735T3
Authority
DK
Denmark
Prior art keywords
compositions
methods
adipocyte function
modulating adipocyte
modulating
Prior art date
Application number
DK04795629T
Other languages
English (en)
Inventor
Ronald Kahn
Yu-Hua Tseng
Atul Butte
Original Assignee
Joslin Diabetes Center Inc
Childrens Hospital Boston
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Joslin Diabetes Center Inc, Childrens Hospital Boston filed Critical Joslin Diabetes Center Inc
Application granted granted Critical
Publication of DK1677735T3 publication Critical patent/DK1677735T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1808—Epidermal growth factor [EGF] urogastrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Child & Adolescent Psychology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
DK04795629T 2003-10-17 2004-10-18 Fremgangsmåder og sammensætninger til modulering af adipocytfunktion DK1677735T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51228303P 2003-10-17 2003-10-17
PCT/US2004/034491 WO2005037232A2 (en) 2003-10-17 2004-10-18 Methods and compositions for modulating adipocyte function

Publications (1)

Publication Number Publication Date
DK1677735T3 true DK1677735T3 (da) 2014-10-27

Family

ID=34465335

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04795629T DK1677735T3 (da) 2003-10-17 2004-10-18 Fremgangsmåder og sammensætninger til modulering af adipocytfunktion

Country Status (4)

Country Link
US (3) US7576052B2 (da)
EP (2) EP2441474B1 (da)
DK (1) DK1677735T3 (da)
WO (1) WO2005037232A2 (da)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6887674B1 (en) 1998-04-13 2005-05-03 California Institute Of Technology Artery- and vein-specific proteins and uses therefor
US7381410B2 (en) * 2003-03-12 2008-06-03 Vasgene Therapeutics, Inc. Polypeptide compounds for inhibiting angiogenesis and tumor growth
US7585967B2 (en) * 2003-03-12 2009-09-08 Vasgene Therapeutics, Inc. Nucleic acid compounds for inhibiting angiogenesis and tumor growth
WO2005037232A2 (en) 2003-10-17 2005-04-28 Joslin Diabetes Center, Inc. Methods and compositions for modulating adipocyte function
ATE492564T1 (de) 2004-03-12 2011-01-15 Vasgene Therapeutics Inc Ephb4-bindende antikörper zur inhibierung von angiogenese und tumorwachstum
WO2005090406A2 (en) * 2004-03-12 2005-09-29 Vasgene Therapeutics, Inc. Antibodies binding to ephb4 for inhibiting angiogenesis and tumor growth
ES2529451T3 (es) 2004-09-23 2015-02-20 Vasgene Therapeutics, Inc. Compuestos polipeptídicos para inhibir la angiogénesis y el crecimiento tumoral
WO2006130690A2 (en) 2005-06-01 2006-12-07 Joslin Diabetes Center, Inc. Methods and compositions for inducing brown adipogenesis
WO2007099345A1 (en) * 2006-03-02 2007-09-07 Betagenon Ab Medical use of bmp-2 and/ or bmp-4
AU2009244308A1 (en) * 2008-05-06 2009-11-12 Joslin Diabetes Center, Inc. Methods and compositions for inducing brown adipogenesis
FR2932818B1 (fr) * 2008-06-23 2015-12-04 Centre Nat Rech Scient Lignee d'adipocytes bruns humains et procede de differenciation a partir d'une lignee de cellules hmads.
EP2396026A2 (en) * 2009-02-12 2011-12-21 Stryker Corporation Compositions and methods for minimally-invasive systemic delivery of proteins including tgf- superfamily members
EP2396025A2 (en) * 2009-02-12 2011-12-21 Stryker Corporation Peripheral administration of proteins including tgf-beta superfamily members for systemic treatment of disorders and disease
US20110046047A1 (en) * 2009-05-20 2011-02-24 Joslin Diabets Center, Inc. Bone Morphogenetic Proteins for Appetite Control
US20120135927A1 (en) * 2009-05-21 2012-05-31 Joslin Diabetes Center, Inc. Bone morphogenetic proteins for the treatment of insulin resistance
US9044606B2 (en) 2010-01-22 2015-06-02 Ethicon Endo-Surgery, Inc. Methods and devices for activating brown adipose tissue using electrical energy
US8476227B2 (en) 2010-01-22 2013-07-02 Ethicon Endo-Surgery, Inc. Methods of activating a melanocortin-4 receptor pathway in obese subjects
EP2605798A1 (en) 2010-07-12 2013-06-26 Universidad Autònoma de Barcelona Gene therapy composition for use in diabetes treatment
JP2013536693A (ja) * 2010-09-01 2013-09-26 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 脂肪生成および筋線維芽細胞分化を制御する薬剤についての細胞培養スクリーニング
US20150147292A1 (en) * 2011-09-15 2015-05-28 Joslin Diabetes Center, Inc. Novel surface markers for adipose tissue
EP2692868A1 (en) 2012-08-02 2014-02-05 Universitat Autònoma De Barcelona Adeno-associated viral (AAV) vectors useful for transducing adipose tissue
WO2015127474A1 (en) 2014-02-24 2015-08-27 Energesis Pharmaceuticals, Inc. Methods and compositions for inducing differentiation of human brown adipocyte progenitors
US11419916B2 (en) 2012-09-11 2022-08-23 Energesis Pharmaceuticals, Inc. Methods and compositions for inducing differentiation of human brown adipocyte progenitors
KR20150088841A (ko) 2012-11-25 2015-08-03 더 리전트 오브 더 유니버시티 오브 캘리포니아 피하 지방생성을 자극하는 펩타이드
US10632175B2 (en) 2013-03-04 2020-04-28 Joslin Diabetes Center, Inc. Exercise-regulated adipokines as therapy for diabetes management
SG10201913751RA (en) 2013-05-06 2020-03-30 Scholar Rock Inc Compositions and methods for growth factor modulation
WO2015171928A2 (en) * 2014-05-07 2015-11-12 Joslin Diabetes Center, Inc. Methods and compositions for induction of ucp1 expression
US10844102B2 (en) 2014-05-28 2020-11-24 The Regents Of The University Of California Peptides, compositions, and methods for stimulating subcutaneous adipogenesis
EP3194430A1 (en) * 2014-09-16 2017-07-26 Universitat Autònoma De Barcelona Adeno-associated viral vectors for the gene therapy of metabolic diseases
US10092738B2 (en) 2014-12-29 2018-10-09 Ethicon Llc Methods and devices for inhibiting nerves when activating brown adipose tissue
US10080884B2 (en) 2014-12-29 2018-09-25 Ethicon Llc Methods and devices for activating brown adipose tissue using electrical energy
WO2016110518A1 (en) 2015-01-07 2016-07-14 Universitat Autònoma De Barcelona Single-vector gene construct comprising insulin and glucokinase genes
US20240058390A1 (en) * 2020-12-16 2024-02-22 The Administrators Of The Tulane Educational Fund Wnt+ adipocytes, exosomes from wnt+ adipocytes, and methods of making and using them

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3023787A1 (de) 1980-06-25 1982-01-21 Studiengesellschaft Kohle mbH, 4330 Mülheim Verfahren zur erhoehung der inkorporation und der expression von genetischem material in die kerne von intakten zellen mit hilfe von liposomen
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
JP2703893B2 (ja) 1985-07-05 1998-01-26 ホワイトヘッド・インスティテュ−ト・フォ−・バイオメディカル・リサ−チ 外来遺伝子物質を発現する上皮細胞
US5366875A (en) 1986-07-01 1994-11-22 Genetics Institute, Inc. Methods for producing BMP-7 proteins
US5187076A (en) 1986-07-01 1993-02-16 Genetics Institute, Inc. DNA sequences encoding BMP-6 proteins
ZA874681B (en) 1986-07-01 1988-04-27 Genetics Inst Novel osteoinductive factors
EP0349578B2 (en) 1987-03-02 1998-10-28 Enzon Labs Inc. Organism carrying a Single Chain Antibody Domain at its surface.
JP2627899B2 (ja) 1987-08-19 1997-07-09 株式会社 ビタミン研究所 遺伝子封入リポソームの製法
WO1989002468A1 (en) 1987-09-11 1989-03-23 Whitehead Institute For Biomedical Research Transduced fibroblasts and uses therefor
JP2914692B2 (ja) 1987-12-11 1999-07-05 ホワイトヘツド・インスチチユート・フオー・バイオメデイカル・リサーチ 内皮細胞の遺伝子修飾
EP0400047B1 (en) 1988-02-05 1997-04-23 Whitehead Institute For Biomedical Research Modified hepatocytes and uses therefor
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
HU208573B (en) 1988-09-06 1993-11-29 Asarco Inc Burner of large activity for melting copper
US5198346A (en) 1989-01-06 1993-03-30 Protein Engineering Corp. Generation and selection of novel DNA-binding proteins and polypeptides
US5096815A (en) 1989-01-06 1992-03-17 Protein Engineering Corporation Generation and selection of novel dna-binding proteins and polypeptides
US4997828A (en) * 1989-02-14 1991-03-05 The Rockefeller University Method of weight control by low level administration of cobalt protoporphyrin or cobalt mesoporphyrin
US5328470A (en) 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
ATE157012T1 (de) 1989-11-03 1997-09-15 Univ Vanderbilt Verfahren zur in vivo-verabreichung von funktionsfähigen fremden genen
JP3249516B2 (ja) 1990-10-31 2002-01-21 ソマティクス セラピー コーポレイション 遺伝子治療のためのレトロウイルスのベクター
DE69129154T2 (de) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
US5318898A (en) 1991-04-02 1994-06-07 Genetics Institute, Inc. Production of recombinant bone-inducing proteins
US5716644A (en) 1992-06-11 1998-02-10 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5674534A (en) 1992-06-11 1997-10-07 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5385887A (en) 1993-09-10 1995-01-31 Genetics Institute, Inc. Formulations for delivery of osteogenic proteins
US5399677A (en) 1993-12-07 1995-03-21 Genetics Institute, Inc. Mutants of bone morphogenetic proteins
US7625697B2 (en) 1994-06-17 2009-12-01 The Board Of Trustees Of The Leland Stanford Junior University Methods for constructing subarrays and subarrays made thereby
GB9503492D0 (en) 1995-02-22 1995-04-12 Ed Geistlich S Hne A G F R Che Chemical product
US5773252A (en) * 1995-06-05 1998-06-30 Human Genome Sciences, Inc. Fibroblast growth factor 15
US5695937A (en) 1995-09-12 1997-12-09 The Johns Hopkins University School Of Medicine Method for serial analysis of gene expression
US5854033A (en) 1995-11-21 1998-12-29 Yale University Rolling circle replication reporter systems
US6048964A (en) 1995-12-12 2000-04-11 Stryker Corporation Compositions and therapeutic methods using morphogenic proteins and stimulatory factors
US5707112A (en) * 1996-05-03 1998-01-13 Magna Lomason Corporation Linear recliner with memory seatback dump mechanism
US6498142B1 (en) 1996-05-06 2002-12-24 Curis, Inc. Morphogen treatment for chronic renal failure
US6426411B1 (en) 1997-05-30 2002-07-30 Dana-Farber Cancer Institute PGC-1, a novel brown fat pparγ coactivator
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
US6245740B1 (en) 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
JP3207823B2 (ja) 1999-04-28 2001-09-10 リノール油脂株式会社 共役リノール酸を有効成分とする褐色脂肪増加剤
US6548739B2 (en) 1999-06-18 2003-04-15 City Of Hope Method for activating peroxisome proliferator activated receptor-γ
US20020001825A1 (en) 2000-03-31 2002-01-03 Nobuyuki Itoh Fibroblast growth factor-like molecules and uses thereof
WO2002012887A2 (en) 2000-08-08 2002-02-14 Millennium Pharmaceuticals, Inc. Methods and compositions for the diagnosis and treatment of brown adipose cell disorders
CA2431552A1 (en) 2000-11-06 2002-05-16 Thrasos, Inc. Screening methods for bone morphogenetic mimetics
EP1368462B1 (en) 2001-01-22 2007-08-01 Curagen Corporation Bfit (brown fat inducible thioesterase) polypeptides and polynucleotides and their use
AU2002352148A1 (en) 2001-06-29 2003-03-03 Abbott Gmnh & Co. Kg Bis-aryl thiazole derivatives
AU2002331898A1 (en) 2001-09-24 2003-04-07 Board Of Supervisors Of Louisiana State Universityand Agricultural And Mechanical College Induction of brown adipocytes by transcription factor nfe2l2
US20030162706A1 (en) 2002-02-08 2003-08-28 The Procter & Gamble Company Angiogenesis modulating proteins
AU2003228355A1 (en) 2002-03-22 2003-10-13 Joslin Diabetes Center, Inc. Adipocytes and uses thereof
CA2497048A1 (en) * 2002-08-28 2004-03-11 Curis, Inc. Conjoint administration of morphogens and ace inhibitors in treatment of chronic renal failure
WO2004044556A2 (en) 2002-11-12 2004-05-27 Becton, Dickinson And Company Diagnosis of sepsis or sirs using biomarker profiles
US7355049B2 (en) * 2003-06-24 2008-04-08 Hoffmann-La Roche Inc. Biaryloxymethylarenecarboxylic acids as glycogen synthase activator
WO2005002527A2 (en) 2003-07-03 2005-01-13 Massachusetts Institute Of Technology Sirt1 modulation of adipogenesis and adipose function
WO2005037232A2 (en) 2003-10-17 2005-04-28 Joslin Diabetes Center, Inc. Methods and compositions for modulating adipocyte function
WO2005042730A2 (en) 2003-11-04 2005-05-12 Biomaster, Inc. Method and system for preparing stem cells from fat tissue
US7691823B2 (en) 2004-03-05 2010-04-06 University Of Massachusetts RIP140 regulation of glucose transport
JP2008500816A (ja) 2004-03-31 2008-01-17 ゼンコー・インコーポレイテッド 改善された性質を有するｂｍｐ−７変異体
US7825098B2 (en) 2005-04-04 2010-11-02 Joslin Diabetes Center, Inc. Methods and compositions for modulating Necdin function
WO2006130690A2 (en) 2005-06-01 2006-12-07 Joslin Diabetes Center, Inc. Methods and compositions for inducing brown adipogenesis
US7771995B2 (en) 2005-11-14 2010-08-10 Merial Limited Plasmid encoding human BMP-7
US8956825B2 (en) 2007-05-24 2015-02-17 The United States Of America As Represented By The Department Of Veterans Affairs Intranuclear protein transduction through a nucleoside salvage pathway

Also Published As

Publication number Publication date
EP2441474B1 (en) 2015-08-05
US8178492B2 (en) 2012-05-15
US9132169B2 (en) 2015-09-15
US20050187154A1 (en) 2005-08-25
WO2005037232A3 (en) 2007-07-12
EP2441474A1 (en) 2012-04-18
EP1677735A4 (en) 2009-07-01
US20110117049A1 (en) 2011-05-19
US7576052B2 (en) 2009-08-18
WO2005037232A2 (en) 2005-04-28
EP1677735A2 (en) 2006-07-12
US20120251457A1 (en) 2012-10-04
EP1677735B1 (en) 2014-07-23

Similar Documents

Publication Publication Date Title
DK1677735T3 (da) Fremgangsmåder og sammensætninger til modulering af adipocytfunktion
DK1638999T3 (da) Sammensætninger og fremgangsmåder til øgning af knoglemineralisering
DK1910395T3 (da) Sammensætninger og fremgangsmåder til modulation af SMN2-splejsning
DK1575416T3 (da) Fremgangsmåder til diagnosticering af præeklampsi
NO20200671A1 (no) Sammensetninger og fremgangsmåter for modulering av hemostase
DK1504126T3 (da) Fremgangsmåde til regulering af genekspression
DK1656370T3 (da) Heterocykliske biarylforbindelser og fremgangsmåder til fremstilling og anvendelse af samme
DK1628530T3 (da) Fremgangsmåder og sammensætninger til forebyggelse og behandling af sepsis
DK1879573T3 (da) Modulatorer af indolamin 2,3-dioxygenase og fremgangsmåder til anvendelse deraf
DK1638750T3 (da) Fremgangsmåder til fremstilling af gelplader
DK1667986T3 (da) Acetonesolvat af dimethoxydocetaxel og fremgangsmåde til fremstilling heraf
DK1858864T3 (da) Stabiliserede sammensætninger af flygtige alkyleringsmidler og fremgangsmåder til anvendelse deraf
DK1776753T3 (da) System og fremgangsmåde til strømmodus-amplitudemodulation
DK1644021T3 (da) Fremgangsmåder og sammensætninger til behandlingen af gastrointestinale sygdomme
DK1948852T3 (da) Hovedelektrode og fremgangsmåde til dannelse af hovedelektroden
DK1668141T3 (da) Fremgangsmåder til forbedring af planters tørketolerance og fremgangsmåder dertil
DK3395339T3 (da) Hurtigt opløsende formulering af cinacalcet-hcl
DK1824475T3 (da) Fremgangsmåde til oprensning af trans-(-)-delta9-tetrahydrocannabinol og trans-(+)-delta9-tetrahydrocannabinol
DK1664343T3 (da) Fremgangsmåder og sammensætninger til generering af kimcelle humane antistofgener
DK1563069T3 (da) Sammensætninger og systemer til genregulering
DK1794174T3 (da) Fremgangsmåder og sammensætninger til hæmning af medfødte immunresponser og autoimmunitet
ATE456558T1 (de) Gabanerge modulatoren
DK1509990T3 (da) Konfiguration og fremgangsmåde til beskyttelse af omformerorganer
DK1532569T3 (da) Fremgangsmåde og indretning til kodning af genstande
DK1457208T3 (da) Fremgangsmåde og farmaceutiske præparater til pålidelig opnåelse af acceptable serumtestosteronniveauer